John Abraham: Telomere Biology Disorders – From Bench to Bedside
John Abraham, Assistant Professor at Christian Medical College and Hospital, shared a post on Linkedin about a recent article by Madeline Franke et al., published in Haematologica, adding:
“Telomere Biology Disorders (TBD): From Bench to Bedside
Recently revisited an excellent review in Haematologica (March 2026) by Madeline Franke et al., focusing on the diagnosis and management of adult telomere biology disorders.
Here are key takeaways
Core concept
TBD represent inherited defects in telomere maintenance leading to short telomeres, genomic instability, and multisystem disease.
Biology simplified
Telomeres (TTAGGG repeats) plus telomerase plus shelterin complex
- Maintain chromosomal integrity
- Progressive shortening triggers cell senescence and malignancy risk
Classification
- Short telomere syndromes (TBD) – organ failure, aging phenotype
- Long telomere syndromes (CPLT) – paradoxical ↑ cancer risk
Genetics
Mutations in key genes (TERT, TERC, DKC1, RTEL1, TINF2)
- Affect telomerase activity, trafficking, or telomere protection
Clinical spectrum (Adults)
- Bone marrow failure
- Interstitial lung disease (often the presenting feature)
- Liver fibrosis/portal hypertension
- Premature aging features
Cancer and hematology Risk
- MDS (~500 fold increase risk)
- AML (20–70 fold increase risk)
- Clonal hematopoiesis plays a central role
Adaptive vs maladaptive clones (TP53, U2AF1)
Diagnosis
- Flow-FISH is clinical gold standard
- Genetic testing essential
- Up to 40% may lack identifiable mutations
Unique concepts
- Genetic anticipation – earlier, more severe disease
- Phenocopying – TBD phenotype without mutation
Management
- Androgens (e.g., danazol) – potential telomere elongation (mixed evidence)
- Transplant remains definitive (HSCT / lung / liver)
Requires reduced-intensity conditioning
Surveillance
- CBC plus marrow monitoring
- Cancer screening (H and N, skin, anogenital)
- Pulmonary and liver evaluation
Multidisciplinary care is key
Future directions
- Gene editing (ZSCAN4, TINF2)
- Telomerase-targeted therapies
Early-phase clinical trials underway
Take-home
Think TBD in:
- Unexplained cytopenias plus ILD plus family history
- Early greying plus marrow failure
- ‘Atypical’ MDS/AML in younger patients
Early recognition – better outcomes.”
Title: Diagnosis and management of adult telomere biology disorders
Authors: Madeline Franke, Alejandro Ferrer, Mrinal M. Patnaik
Read the Full Article on Haematologica
Stay updated with Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC